两个月内达成超50亿美元潜在规模交易,诺和诺德疯狂押注新一代减重疗法

第一财经
14 May

诺和诺德正在疯狂斥重资押注减重疗法,以占领新一代药物研发的先机。欧洲当地时间5月14日,诺和诺德宣布,已与美国生物科技公司Septerna达成合作及授权协议,共同开发用于治疗肥胖症、2型糖尿病和其他心脏代谢疾病的口服小分子药物,该协议的潜在价值预计高达22亿美元,其中包括2亿美元的预付款。这也是诺和诺德在不到两个月内,在减重药领域的又一次大手笔投资。今年3月,诺和诺德宣布与生物医药公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10